HEALWELL AI Inc. develops and commercializes healthcare artificial intelligence software for preventative care, with a focus on clinical decision support, early disease identification, and workflow tools for healthcare providers. News about HWAIF commonly covers the company’s DARWEN™ AI platform, Smart Search, Smart Summary, Smart ID, and the use of AI-enriched clinical data to support real-world evidence across disease areas.
Company updates also include revenue and Adjusted EBITDA reporting, integration of Orion Health, enterprise health-system and Health Information Exchange software contracts, customer renewals, scientific publications, conference participation, and board or governance changes. HEALWELL trades on the Toronto Stock Exchange as AIDX and on the OTCQX market as HWAIF.
HEALWELL AI (OTCQX:HWAIF) announced its 47th peer-reviewed publication validating the DARWEN™ AI platform, with new research published in the Journal of Crohn's and Colitis and presented at ECCO on March 12, 2026. HEALWELL also secured three additional 2026 conference acceptances across diabetes, dermatology and IBD.
The studies show DARWEN™ can transform unstructured EHR data into research-ready real-world evidence, analyze millions of clinical records, and support Medical Affairs and market access initiatives with pharmaceutical partners.
HEALWELL AI (TSX: AIDX) (OTCQX: HWAIF) will release its Fiscal Fourth Quarter and Year End 2025 financial results for the period ended December 31, 2025, on March 19, 2026. A conference call and simultaneous webcast to discuss results will be held on March 20, 2026 at 8:30 AM ET.
Management hosting the call: James Lee, Chief Executive Officer; Dr. Alexander Dobranowski, President; and Anthony Lam, Chief Financial Officer. Webcast and dial-in details provided for live access.
HEALWELL AI (OTCQX: HWAIF) announced a signed multi‑million dollar, multi‑year U.S. Health Information Exchange (HIE) software contract, expanding its enterprise interoperability footprint and supporting secure data exchange for millions of patient lives.
The company reported renewed pipeline momentum, coordinated Orion Health and VeroSource bid activity, and integration of SMART Identify, SMART Search and SMART Summary into the Amadeus AI platform to drive enterprise AI commercialization.
HEALWELL (OTCQX:HWAIF) will participate in three investor conferences in March 2026: TD Cowen (Boston, Mar 2-4), Scotiabank TMT (Toronto, Mar 3-4) and ROTH (Dana Point, Mar 22-24).
Dr. Alexander Dobranowski will present and hold investor meetings, including a TD Cowen presentation on Mar 3 and a ROTH panel on Mar 23 titled Technologies Advancing Healthy Aging.
HEALWELL AI (OTCQX:HWAIF) announced its first contracted AI deployment in the Middle East and expanded active deployments across Canada and the United States on February 26, 2026. The Company is deploying SMART Identify, SMART Search, and SMART Summary in multiple healthcare systems, marking cross‑border commercial momentum and platform scalability.
HEALWELL says deployments span frontline care environments and that contracted revenue now exists across Canada, the U.S., and the Middle East, while the company reports a growing pipeline for broader enterprise expansion.
HEALWELL AI (OTCQX: HWAIF) and WELL Health launched WELLTRUST™ on February 19, 2026, a consent-first data governance and patient-identification platform deployed across WELL-operated clinics in Canada. WELLTRUST uses patient-controlled consent and HEALWELL's DARWEN™ AI to identify high-fit patients for clinical trials while preserving privacy and compliance.
The platform supports contact consent, unified privacy controls, AI-enabled recruitment, and a governance layer to meet Canadian regulatory standards.
HEALWELL AI (OTCQX: HWAIF) provided a corporate update on February 12, 2026, outlining platform integration, product rollouts and portfolio simplification.
The company unified Khure and Pentavere into a DARWEN-powered AI engine, plans a North American Amadeus AI launch in 1H-26 (international late 2026), reports early commercial traction via Orion-Verosource initiatives, notes four Q4-2025 publications, and is assessing a USD $2M strategic investment vehicle holding an interest in xAI/SpaceX.
HEALWELL AI (OTCQX: HWAIF) provided additional disclosure after an OSC request to clarify forward-looking statements tied to its November 3, 2025 strategic divestments.
Key factual points: continuing-operations revenue of $30.4M in Q3-2025 (annualized ≈ $120M), a Q3-2025 Adjusted EBITDA of $0.7M versus an Adjusted EBITDA loss of $2.8M in Q3-2024, and a net loss from continuing operations of $16M in Q3-2025. The company completed sales of two non-core businesses and contributed two others to a clinical research joint venture following the Orion Health acquisition (effective April 1, 2025).
The company emphasized assumptions and risks underlying its revenue run-rate and AI capability claims and referenced peer-reviewed validations and industry awards for its DARWEN platform.
HEALWELL AI (OTCQX: HWAIF) appointed Ian Kidson to its Board of Directors, effective December 10, 2025.
Kidson brings decades of financial, governance, and healthcare-related corporate leadership across public and private companies in Canada and the U.S., including roles as CFO at Docebo (2019–2021), CFO and CEO at Apollo Health Corp., EVP & CFO at Progressive Waste Solutions (before its 2016 merger with Waste Connections), and senior capital markets positions at CIBC Wood Gundy and TD Capital Mezzanine Partners. HEALWELL said his financial expertise and experience guiding organizations through growth will support its focus on early identification and detection of disease.
HEALWELL (OTCQX: HWAIF) reported Q3-2025 revenue of $30.4M, a 354% increase year‑over‑year driven largely by the Orion Health acquisition. Subscription, support and maintenance revenue rose to $21.0M (+535%). The company posted positive Adjusted EBITDA of $0.7M versus a loss of $2.8M in Q3‑2024, its second consecutive quarter of positive adjusted EBITDA. IFRS net loss from continuing operations was $16.0M (up 83% YoY). HEALWELL exercised its call option to acquire the remaining 49% of Pentavere and launched AmadeusAI integrating DARWEN™. Subsequent divestments and transactions strengthened the balance sheet with approximately $9.7M in cash proceeds, positioning the company as a pure‑play AI, SaaS and services healthcare provider.